Congress Wealth Management LLC DE Sells 22,132 Shares of Zoetis Inc. (NYSE:ZTS)

Congress Wealth Management LLC DE decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 20.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,635 shares of the company’s stock after selling 22,132 shares during the period. Congress Wealth Management LLC DE’s holdings in Zoetis were worth $13,790,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after buying an additional 120,158 shares during the last quarter. Napatree Capital LLC lifted its holdings in Zoetis by 15.2% in the fourth quarter. Napatree Capital LLC now owns 3,123 shares of the company’s stock valued at $509,000 after acquiring an additional 411 shares during the period. Stevens Capital Management LP purchased a new position in Zoetis in the fourth quarter worth about $548,000. LPL Financial LLC grew its stake in shares of Zoetis by 10.4% during the 4th quarter. LPL Financial LLC now owns 396,851 shares of the company’s stock valued at $64,722,000 after purchasing an additional 37,275 shares during the period. Finally, Fox Run Management L.L.C. increased its position in shares of Zoetis by 512.3% during the 4th quarter. Fox Run Management L.L.C. now owns 9,148 shares of the company’s stock valued at $1,490,000 after purchasing an additional 7,654 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.1 %

NYSE ZTS opened at $163.22 on Tuesday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market cap of $73.09 billion, a PE ratio of 29.84, a P/E/G ratio of 2.78 and a beta of 0.94. The stock’s 50 day moving average is $166.70 and its 200 day moving average is $175.22.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZTS. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $215.90.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,862 shares of company stock valued at $312,254. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.